Today TecMed, Inc. announced that its optical measurement IP has set a new standard in blood glucose measurement technologies. TecMed's IP is reported to have the greatest precision in the measurement of blood glucose, and other chiral molecules, compared to other technologies currently commercially available.
TecMed, Inc.'s IP could potentially replace and improve existing measurement, and light energy management, technologies across both medical and non-medical industries due to an exceedingly precise control of light energy. The applications for the light-based IP technology include blood glucose monitoring, lasers, sensors, fiber optics, and telecommunications, among many others. Each of these applications provides solutions to unmet problems in extremely large and growing global markets.
TecMed, Inc. also announced today that it is continually expanding its intellectual property portfolio with corresponding patent protections. The current portfolio includes four issued patents with continuations and extensions. In December, 2013, TecMed, Inc. received a written recommendation for approval of core claims from the international Examiner reviewing its pending PCT application. This PCT application is specific to IP for automated patient blood glucose monitoring in perioperative and critical care environments. Several additional patents are in varying stages of the application process in the U.S. and through the PCT.
In more than 30 blind and double-blind human studies, TecMed's optical measurement technology has demonstrated a 40-50% improvement in accuracy over clinical point of care "Gold Standard" instruments and methods. This innovative IP provides solutions for known problems of blood glucose measurement including accuracy, frequency of measure, timeliness of data, excessive labor costs, and costly disposables. Together, these integrated achievements provide an unparalleled and cost effective solution for patient blood glucose measurement in perioperative and critical care settings that also sets an unprecedented standard of accuracy in blood glucose measurement.
About TecMed, Inc.
Founded in 1995, TecMed is a privately-held intellectual property company incorporated in the State of Wyoming, organized to create innovative technologies, conduct original research, and advance development in the field of measurement technologies.
TecMed's fundamental business model advances the formation of outside business relationships in the medical device and healthcare industries with a focus on licensing its IP solutions in blood glucose measurement technology.